[摘 要] 目的：评价DC-CIK细胞免疫治疗辅助西妥昔单抗联合CAPEOX（奥沙利铂 + 卡培他滨）化疗方案治疗全RAS基因 野生型、BRAF基因野生型晚期结直肠癌（CRC）的临床疗效与安全性。方法：回顾性分析2020年12月至2023年10月期间东部 战区总医院肿瘤科收治的52例晚期CRC的临床资料，其中对照组与观察组分别为26例。观察组在对照组化疗基础上给予 DC-CIK细胞治疗，统计患者的临床疗效和不良反应，分析患者的近期疗效、生活质量评分、化疗不良反应发生情况，以及治疗前 后肿瘤标志物和免疫指标的变化。结果：与对照组相比，观察组晚期CRC患者的疾病控制率（DCR）、生活质量均明显提高（均 P < 0.05），化疗后腹泻或便秘的发生率、肿瘤标志物CA72-4均明显降低（均P < 0.05），NK细胞计数明显上升（P < 0.05）。结论： 在晚期CRC患者行DC-CIK细胞免疫治疗辅助西妥昔单抗联合CAPEOX化疗方案治疗安全可行，能够显著提高DCR，为患者带 来显著的临床获益。

[Abstract] Objective: To evaluate the clinical efficacy and safety of DC-CIK cell immunotherapy as an adjuvant to cetuximab combined with CAPEOX (oxaliplatin + capecitabine) chemotherapy regimen in the treatment of advanced colorectal cancer (CRC) with all RAS gene wild-type and BRAF gene wild-type. Methods: A retrospective analysis was conducted on the clinical data of 52 cases of advanced CRC treated in the Oncology Department of in the General Hospital of the Eastern Theatre Command between December 2020 and October 2023, with 26 cases in the control group and the observation group respectively. The observation group received DC-CIK cell therapy in addition to chemotherapy given to the control group. The clinical efficacy and adverse reactions of patients were recorded, and the recent efficacy, quality of life score, incidence of chemotherapy adverse reactions, the changes in tumour markers, and immune indicators before and after treatment were analysed. Results: Compared with those in the control group, the disease control rate (DCR) and quality of life of advanced CRC patients in the observation group were significantly improved (both P < 0.05). The incidence of diarrheal/constipation and tumour marker CA72-4 were significantly reduced (all P < 0.05), and the NK cell count increased significantly (P < 0.05). Conclusion: DC-CIK cell immunotherapy, when used as an adjuvant to cetuximab in combination with the CAPEOX chemotherapy regimen in patients with advanced CRC, is safe and feasible. It can significantly improve the DCR and bring significant clinical benefits to patients.

东部战区总医院院管课题（No. 22JCYYYB1）